Clinical Trials Of Recombinant Human Brain Natriuretic Eptide(heart Xinhuosu) On Postoperative Prognostic Impact In Patients With Acute Anterior Myocardial Infarction Emergency Intervention

Objectives: Verify recombinant human brain natriuretic peptide (XinHuoSu)involved in the postoperative prognosis in patients with acute anterior myocardialinfarction emergency.Methods: Select March2012To March2013treatment in the People’s Hospital ofLiaoning Province,30cases of acute anterior myocardial infarction, Killip I-III levelline after primary percutaneous coronary intervention patients.The patients wererandomly divided into recombinant human brain natriuretic peptide (XinHuoSu) groupof18cases, this treatment group,12cases more than the control group. Two groups ofpatients after acute anterior myocardial infarction herein are emergency coronaryintervention. Recorded in the preoperative blood pressure, laboratory parameters,18-lead ECG, to the treatment group recombinant human brain natriuretic peptideweight load factors bolus. And then by radial or femoral artery puncture underwentcoronary interventional procedures. After conventional to low molecular weight heparin,anticoagulant medication, if necessary, to maintain alternate tirofiban, B-blockers,diuretics, digoxin, digitalis treatment. The course of treatment, as appropriate, digitalis,dopamine, dobutamine, or rice milrinone inotropic agents, Treatment group on the basisof conventional drugs, according to the body weight the amount of XinHuoSuintravenous uniform pumped and maintenance dose72hours. The XinHuoSu isShenzhen CMS production. Were recorded at baseline and after intervention vital signs,chest pain extent, biochemical parameters, ECG and echocardiography changes. Recordafter24-hour urine output, recorded on admission and after treatment one week SV, leftventricular fractional shortening, LVD and LVEF, On admission and immediately after treatment, the first day of the seventh day, respectively, measured BNP values, The wererecorded adverse cardiac events occurred within1month, with spass17.0software forstatistical analysis.Result:1.rh-BNP group and the control group in patients with chest pain havevarying degrees of ease, the difference was not statistically significant (P>0.05).2.Rh-BNP group and the control group in patients with systolic and diastolic bloodpressure were decreased, but the difference was not statistically significant (P>0.05).3.Rh-BNP group and the control group in patients with heart rate did not changesignificantly.4.rh-BNP in patients24-hour urine output compared with the control group ofpatients24-hour urine output slightly, but the difference was not statistically significant(P>0.05).5.Rh-BNP group of patients with CK-MB peak and TNT peak compared with thecontrol group, but the difference was not statistically significant (P>0.05), BNPchanges rh-BNP group and the control group was not statistically significant (P>0.05).6.rh-BNP groups and the control group of patients with changes in serum Sr wasnot statistically significant (P>0.05).7.rh-BNP groups and the control group in patients with SV, left ventricularfractional shortening and LVEF, LA was no statistically significant difference (P>0.05),LVD rh-BNP group and the control group was statistically significant (P <0.05).8.rh-BNP group hypokalemia cases of adverse events in the control group patientswith adverse events and1died was not statistically significant (P>0.05).Conclusion:1.rh-BNP may have a role in the early suppression myocardialremodeling.2.rh-BNP on renal function in patients with no increase in serum Scr, there is acertain security.